Objective: Previous studies suggested a potential role for macrophage colony stimulating factor (CSF-1) in lactogenic differentiation of the breast. The aim of this study was to define the regulation of CSF-1 and its receptor (CSF-1R, the product of c-fms proto-oncogene) by lactogenic hormones in the breast in vivo during pregnancy and lactation and in vitro in organ culture and mammary epithelial cell lines.
Methods: Immunohistochemical staining assays for the expression of CSF-1 and CSF-1R antigens were performjed on sections of breast biopsies from nonpregnant (n = 10), prepartum (n = 4), and postpartum lactating patients (n = 7_) and on sections of human mammary glands culture in the presence of the lctogenic hormones insulin, prolactin, and glucocorticoids. Northern blot analyses were used to study the regulation of CSF-1 and CSF-1R by these same lactogenic hormones in normal and neoplastic mammary epithelial cell lines in cell culture.
Results: Normal, nonlactating mammary epithelium did not express CSF-1R and synthesized only low levels of CSF-1. During lactation, significant levels of both proteins could be observed in the epithelial cells that line actively lactating ducts and alveoli. Very similar increases in epithelial cell expression of CSF-1 and CSF-1R were observed in organ cultures of normal mammary gland biopsies exposed to prolactin, insulin, and glucocorticoids. Colony stimulating factor mRNA levels were increased by prolactin and/or insulin in a normal mammary epithelial cell line, while glucocorticoids had no apparent effect on CSF-1 mRNA levels. In contrast, we found that the levels of CSF-1R transcript are regulated primarily by glucocorticoids in breast carcinoma cells, while prolactin merely modulates the glucocorticoid effect.
Conclusion: The observed increases in the expression of CSF-1 and its receptor during lactogenesis and the regulation of CSF-1/CSF-1R by lactogenic hormones suggests that this cytokine/receptor pair might play a regulatory role in the cellular events leading to the lactogenic differentiation of mammary epithelial cells.
1. Heisterkamp N, Groffen J, Stephenson JR. Isolation of v-fms and its human cellular homology. Virology1983;126:248-258.
2.
2. Rettenmeier CW, Chen JH, Roussel MF, Sherr CJ. The product of the c-fms proto-oncogene: a glycoprotein with associated tyrosine kinase activity. Science1985;228:320-322.
3.
3. Sherr CJ. The fms oncogene. Biochim Biophys Acta1988;948:225-243.
4.
4. Woolford JV, Rothwell V, Rohrschneider LR. Charcterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage. MOl Cell Biol1985;5:3458-3466.
5.
5. Sariban E, Mitchell T, Kufe D. Expression of the c-fms protooncogene during human monocytic differentiation. Nature1985;316:64-66.
6.
6. Pollard JW, Bartocci A, Arceci R, Orlovsky A, Ladner MB, Stanley ER. Apparent role of the macrophage growth factor CSF-1 in placental development. Nature1987;330:484-486.
7.
7. Daiter E, Pampfer S, Yeung YG, Barad D, Stanley ER, Pollard JW. Expression of colony-stimulating factor-1 in the human uterus and placenta. J Clin Endoctrinol Metabol1992;74:850-858.
8.
8. Kacinski BM, Scata KA, Carter D, et al. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene1991;6:941-952.
9.
9. Tang RP, Beuvon F, Ojeda M, Mosseri V, Pouillart P, Scholl S. M-CSF (Monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells. M-CSF mediated recruitment of tumour infiltrating monocytes. J Cell Biochem1992;50:350-356.
10.
10. Hara T, Irie K, Saito S, et al. Identification of macrophage colony-stimulating factor in human milk and mammary gland epithelial cells. Pediatr Res1995;37:437-443.
11.
11. Pollard JW, Henninghausen L. Colony-stimulating factor 1 is required for mammary gland development during pregnancy. Proc Natl Acad Sci USA1994;91:9312-9316.
12.
12. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC, Brown EL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest1989;83:921-926.
13.
13. Baiocchi G, Kavanagh JJ, Talpaz M, Wharton JT, Gutterman JU, Kurrock R. Expression of the macrophage colony-stimulating factor and its receptor in gynecologic malignacies. Cancer1991; 67:990-996.
14.
14. Flick MB, Sapi E, Perotta PL, et al. Recognition of activated CSF-1 receptor in breast carcinomas by tyrosine 723 phosphospecific antibody. Oncogene1997;14:2553-2561.
15.
15. Scholl SM, Crocker P, Tang R, Pouillart P, Pollard JW. Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metasasis. Mol Carcinog1993;7:207-211.
16.
16. Kacinski BM, Carter D, Mittal K, et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with co-expression of CSF-1. Am J Pathol1990;137:135-147.
17.
17. Kacinski BM, Carter D, Mittal K, et al. High level expression of fms proto-oncogene mRNA is observed in clinically aggressive human endometrial adenocarcinomas. Int J Radiat Oncol Biol Phys1988;15:823-829.
18.
18. Bartocci A, Pollard JW, Stanley ER. Regulation of colony stimulating factor-1 during pregnancy. J Exp Med1986;164:956-961.
19.
19. Sapi E, Flick MB, Gilmore-Hebert M, Rodov S, Kacinski BM. Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene1995;10:529-542.
20.
20. Topper YJ, Freeman TCS. Multiple hormone interactions in the development biology of the mammary gland. Physiol Rev1980;60:1049-1094.
21.
21. Hynes NE, Taverna D, Harwetz IM, et al. Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the β-casein gene in mouse mammary epithelial cells. Mol Cell Biol1990;10:4027-4034.
22.
22. Stanley ER. The macrophage colony stimulating factor CSF-1. In: Colwick SP, Kaplan NO, eds. Methods in enzymology. San Diego: Academic Press, 1985;564-587.
23.
23. Coussens L, Van Beveren C, Smith D, et al. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature1986;320:277-280.
24.
24. Yoshimura M, Banerjee Mr, Oka T. Nucleotide sequence of a cDNA encoding mouse β-casein. Nucleic Acids Res1986;14:8224-8224.
25.
25. Fuh G, Wells JA. Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J Biol Chem1995;270:13133-13137.
26.
26. Cappeletti V, Ruedl C, Miodini P, et al. Paracrine interaction in co-culture of hormone dependent and independent breast cancer cells. Breast Cancer Res Treat1993;26:275-281.
27.
27. Bussman LE, Bussman Em, Charreau EH. Role of receptors for epidermal growth factor and insulin-like growth factors I and II in the differentiation of rat mammary glands from lactogenesis I to lactogenesis II. J Reprod Fertil1996;107:307-314.
28.
28. Sapi E, Flick MB, Rodov S. et al. Independent regulation of invasion and anchorage-independent growth by different autophosphorylation sites of the macrophagee colony-stimulating factor 1 receptor. Cancer Res1996;56:5704-5712.
29.
29. Filderman A. Bruckner A, Kacinski BM, Deng M, Hines G, Remold H. Macrophage colony-stimulating factor (CSF-1) enhances invasiveness in CSF-1 receptor (CSF-1)-positive cancer cell lines. Cancer Res1992;52:3661-3669.
30.
30. Ossowaski L, Biegel D, Reich E. Mammary plasminogen activator: Correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell1979;16:929-940.
31.
31. Talkhoud RS, Chin JR, Unemon EN, Werb Z, Bissell MJ. Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development1991;112:439-449.
32.
32. Eichfeld U, Haerting J, SWchwartz I. Serum prolactin levels of primary breast cancer. Tumordiagnostik Therapie1993;14:194-200.
33.
33. Wang DY, Stepniewska KA, Allen DS, et al. Serum prolactin levels and their relatinoship to survival in women with operable breast cancer. J Clin Epidemiol1995;48:959-968.
34.
34. Patel DD, Bhatavdekar JM, Chikhlikar PR, et al. Node negative breast carcinoma—hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol1996;62:86-92.
35.
35. Wiznitzer I, Benz C. Direct growth-inhibiting effects of the prolactin antagonists burserelin and pergolide on human breast cancer. Proc Am Assoc Cancer Res1984;25:208-208.
36.
36. Biswas R, Vonderhaar BK. Tamoxifen inhibition of prolactin action in the mouse mammary gland. Endocrinology1991;128:532-538.
37.
37. Klijn JGM, deJong FH, Bakker GH, Lamberts SWJ, Rodenburg CJ, Alexieva-Figush J. ANtiprogestins, a new form of endocrine thereapy for human breast cancer. Cancer Res1989;49:2851-2856.
38.
38. Maudelonde T, Romieu G, Ulmann A, et al. First clinical trial of the use of the antiprogestin RU486 in advanced breast cancer. Hormonal manipulation of cancer: peptides, growth factors and new (anti)steroidal agents. New York: Raven Press, 1987.
